Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pfas Policy Options topic
No spam. Unsubscribe anytime.
Committee members probe PFAS policy options: procurement, labeling, biosolids and the cost of remediation
Summary
Minnesota Capital Investment Committee members questioned a Michigan PFAS advocate about biosolids, procurement policy, insurance signals and remediation costs; members cited potential procurement levers and a bipartisan House file as next steps while approving routine minutes.
Committee members used the testimony to explore practical policy levers and implications for Minnesota, focusing on procurement rules, labeling, biosolids management, insurance liabilities and infrastructure costs.
Members asked whether states can use public procurement to drive the market away from products containing intentionally added PFAS. The testifier said Michigan adopted a procurement policy in recent years but implementation has been uneven; she advised clear PFAS definitions and better labeling to enable effective state purchasing rules. “States have the power to drive this market,” she told the committee, but added that implementation and industry response vary.
Discussion also addressed biosolids: members asked how wastewater treatment solids (biosolids) can spread PFAS to farmland and whether wastewater operators and distributors keep records that would allow regulators to trace biosolids distribution. The testifier said some states now require recording biosolids distribution and pre‑treatment requirements for industries discharging to wastewater systems, but allowable PFAS levels in biosolids differ by state.
Members noted that settlements such as those involving 3M have not covered the majority of projected state cleanup costs. A member cited an estimate of up to $20 billion to address wastewater infrastructure statewide. Committee members flagged insurance companies’ reluctance to cover PFAS‑related liabilities as a market signal that could influence manufacturers.
Procedural items: the committee approved the Feb. 26 minutes by unanimous consent and scheduled follow‑up work; members identified House file 33,22 (referenced during discussion) as pending bipartisan legislation that may warrant coordination across committees.
No formal policy votes on PFAS regulation or funding were taken at this meeting; members signaled interest in staff work and future committee discussion to consider procurement pilots, labeling standards and state funding for community testing.
